Pacvue Launches Pacvue Prism, Powering the Industry’s First Agentic Commerce Grid
DoubleVerify Expands DV Authentic AdVantage to Meta and TikTok, an AI-Powered Solution to Optimize Media Quality and Performance
3D AI Studio Launches Flow: Node-Based 3D Workflows That Run in the Browser With No GPU or Setup
Shangri-La Group Debuts ‘Dragonbeat’ with Resounding Success, Cross-Industry Collaborations with Local Creators in Art, Fashion, Gastronomy and Music
EE Power Asia 2026 to Spotlight Technologies Driving the Next Era of Electrification
ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity ISELIN,…
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a…
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform…
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian…
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality…
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued…
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial…
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)…
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid…
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP;…
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla…
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in…
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX:…
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo…
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva,…